Skip to Content

Publications 2012


Chakrabarty A, Bhola NE, Sutton C, Ghosh R, Kuba MG, Dave B, Chang JC, Arteaga CL. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res. 2013 Feb 1;73(3):1190-200. doi: 10.1158/0008-5472.CAN-12-2440. Epub 2012 Nov 29. PubMed PMID: 23204226; PubMed Central PMCID: PMC3563941.

Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res. 2013 Feb 1;19(3):610-9. doi: 10.1158/1078-0432.CCR-12-2024. Epub 2012 Dec 5. PubMed PMID: 23224399; PubMed Central PMCID: PMC3563762.

Friberg A, Vigil D, Zhao B, Daniels RN, Burke JP, Garcia-Barrantes PM, Camper D, Chauder BA, Lee T, Olejniczak ET, Fesik SW. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem. 2013 Jan 10;56(1):15-30. doi: 10.1021/jm301448p. Epub 2012 Dec 17. PubMed PMID: 23244564; PubMed Central PMCID: PMC3646517.

Ashby WJ, Zijlstra A. Established and novel methods of interrogating two-dimensional cell migration. Integr Biol (Camb). 2012 Nov;4(11):1338-50. doi:  10.1039/c2ib20154b. Review. PubMed PMID: 23038152; PubMed Central PMCID: PMC4165521.

Walsh AJ, Poole KM, Duvall CL, Skala MC. Ex vivo optical metabolic measurements from cultured tissue reflect in vivo tissue status. J Biomed Opt. 2012 Nov;17(11):116015. doi: 10.1117/1.JBO.17.11.116015. PubMed PMID: 23117810; PubMed Central PMCID: PMC3484268.

Yankeelov TE, Peterson TE, Abramson RG, Izquierdo-Garcia D, Arlinghaus LR, Li X, Atuegwu NC, Catana C, Manning HC, Fayad ZA, Gore JC. Simultaneous PET-MRI in oncology: a solution looking for a problem? Magn Reson Imaging. 2012 Nov;30(9):1342-56. doi: 10.1016/j.mri.2012.06.001. Epub 2012 Jul 15. Review. Erratum in: Magn Reson Imaging. 2013 Jun;31(5):796. Garcia-Izquierdo, David [corrected to Izquierdo-Garcia, David]. PubMed PMID: 22795930; PubMed Central PMCID: PMC3466373.

Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res. 2012 Oct 15;18(20):5816-28. doi: 10.1158/1078-0432.CCR-12-1141. Epub 2012 Aug 29. PubMed PMID: 22932669; PubMed Central PMCID: PMC3772348.

Shyr Y. Rigorous quantitative sciences integration--the foundation of high-dimensional genomic research. Clin Exp Metastasis. 2012 Oct;29(7):641-3. doi: 10.1007/s10585-012-9508-y. Epub 2012 Jul 15. PubMed PMID: 22798219; PubMed Central PMCID: PMC3485411.

Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. Mol Cancer Ther. 2012 Oct;11(10):2301-5. doi: 10.1158/1535-7163.MCT-12-0511. Epub 2012 Aug 9. PubMed PMID: 22879364; PubMed Central PMCID: PMC3682668.

Kallen ME, Sanders ME, Gonzalez AL, Black JO, Keedy VL, Hande KR, Homlar KC, Halpern JL, Holt GE, Schwartz HS, Coffin CM, Cates JM. Nuclear p63 expression in osteoblastic tumors. Tumour Biol. 2012 Oct;33(5):1639-44. doi: 10.1007/s13277-012-0419-y. Epub 2012 May 25. PubMed PMID: 22623071.

Higginbotham KS, Breyer JP, McReynolds KM, Bradley KM, Schuyler PA, Plummer WD, Freudenthal ME, Trentham-Dietz A, Newcomb PA, Parl FF, Sanders ME, Page DL, Egan KM, Dupont WD, Smith JR. A multistage genetic association study identifies breast cancer risk loci at 10q25 and 16q24. Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1565-73. doi: 10.1158/1055-9965.EPI-12-0386. Epub 2012 Jul 17.PubMed PMID: 22806168; PubMed Central PMCID: PMC3707501.

Geisberg C, Pentassuglia L, Sawyer DB. Cardiac side effects of anticancer treatments: new mechanistic insights. Curr Heart Fail Rep. 2012 Sep;9(3):211-8.doi: 10.1007/s11897-012-0098-4. Review. PubMed PMID: 22752360; PubMed Central PMCID: PMC3693763.

Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012 Jul 1;72(13):3228-37. doi: 10.1158/0008-5472.CAN-11-3747. Epub 2012 May 2. PubMed PMID: 22552284; PubMed Central PMCID: PMC3515079.

Li X, Welch EB, Chakravarthy AB, Xu L, Arlinghaus LR, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Abramson VG, Grau AM, Gore JC, Yankeelov  TE. Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer. Magn Reson Med. 2012 Jul;68(1):261-71. doi: 10.1002/mrm.23205. Epub 2011 Nov 29. PubMed PMID: 22127821; PubMed Central PMCID: PMC3291742.

Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med. 2012 Jul;18(7):1052-9. doi: 10.1038/nm.295. PubMed PMID: 22683778; PubMed Central PMCID: PMC3693569.

Sprung RW, Martinez MA, Carpenter KL, Ham AJ, Washington MK, Arteaga CL, Sanders ME, Liebler DC. Precision of multiple reaction monitoring mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue. J Proteome Res. 2012 Jun 1;11(6):3498-505. doi: 10.1021/pr300130t. Epub 2012 May 7. PubMed PMID: 22530795; PubMed Central PMCID: PMC3368395.

Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, Sánchez V, Koland J, Muller WJ, Arteaga CL, Cook RS. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res. 2012 May 15;72(10):2672-82. doi: 10.1158/0008-5472.CAN-11-3594. Epub 2012 Mar 29. PubMed PMID: 22461506; PubMed Central PMCID: PMC3693553.

Kurley SJ, Bierie B, Carnahan RH, Lobdell NA, Davis MA, Hofmann I, Moses HL, Muller WJ, Reynolds AB. p120-catenin is essential for terminal end bud function and mammary morphogenesis. Development. 2012 May;139(10):1754-64. doi: 10.1242/dev.072769. Epub 2012 Mar 29. PubMed PMID: 22461563; PubMed Central PMCID: PMC3328177.

Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2718-23. doi: 10.1073/pnas.1018001108. Epub 2011 Feb 28. PubMed PMID: 21368164; PubMed Central PMCID: PMC3286932.

Souza-Fagundes EM, Frank AO, Feldkamp MD, Dorset DC, Chazin WJ, Rossanese OW, Olejniczak ET, Fesik SW. A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A. Anal Biochem. 2012 Feb 15;421(2):742-9. doi: 10.1016/j.ab.2011.11.025. Epub 2011 Dec 1. PubMed PMID: 22197419; PubMed Central PMCID: PMC3274598.

Miller TW. Initiating breast cancer by PIK3CA mutation. Breast Cancer Res. 2012 Feb 7;14(1):301. PubMed PMID: 22315990; PubMed Central PMCID: PMC3496136.

Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):221-6. doi: 10.1073/pnas.1115802109. Epub 2011 Dec 16. PubMed PMID: 22178756; PubMed Central PMCID: PMC3252958.

Liu Q, Guo Y, Li J, Long J, Zhang B, Shyr Y. Steps to ensure accuracy in genotype and SNP calling from Illumina sequencing data. BMC Genomics. 2012;13 Suppl 8:S8. doi: 10.1186/1471-2164-13-S8-S8. Epub 2012 Dec 17. PubMed PMID: 23281772; PubMed Central PMCID: PMC3535703.

Ye F, Bauer JA, Pietenpol JA, Shyr Y. Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives. BMC Genomics. 2012;13 Suppl 8:S3. doi: 10.1186/1471-2164-13-S8-S3. Epub 2012 Dec 17. PubMed PMID: 23281588; PubMed Central PMCID: PMC3535706.

Su PF, Chen X, Chen H, Shyr Y. Statistical aspects of omics data analysis using the random compound covariate. BMC Syst Biol. 2012;6 Suppl 3:S11. doi: 10.1186/1752-0509-6-S3-S11. Epub 2012 Dec 17. PubMed PMID: 23281681; PubMed Central PMCID: PMC3524312.

Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012;17(1):1-16. Review. PubMed PMID: 22471661; PubMed Central PMCID: PMC3394454.

Yankeelov TE. Integrating Imaging Data into Predictive Biomathematical and Biophysical Models of Cancer. ISRN Biomath. 2012;2012. pii: 287394. PubMed PMID: 23914302; PubMed Central PMCID: PMC3729405.

Kallen ME, Nunes Rosado FG, Gonzalez AL, Sanders ME, Cates JM. Occasional staining for p63 in malignant vascular tumors: a potential diagnostic pitfall. Pathol Oncol Res. 2012 Jan;18(1):97-100. doi: 10.1007/s12253-011-9426-3. Epub 2011 Jun 13. PubMed PMID: 21667345.

Thiolloy S, Edwards JR, Fingleton B, Rifkin DB, Matrisian LM, Lynch CC. An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment. PLoS One. 2012;7(1):e29862. doi: 10.1371/journal.pone.0029862. Epub 2012 Jan 4. PubMed PMID: 22238668; PubMed Central PMCID: PMC3251607.